Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 27, Issue 16, 2014, Pages 1698-1702

  Taha, Dalal ^a   Kirkby, Sharon ^b   Nawab, Ursula ^a   Dysart, Kevin C ^d   Genen, Linda ^b,c   Greenspan, Jay S ^a   Aghai, Zubair H ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Alere Health   (United States)

^c Northwell Health   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

BPD; NEC; Neonates; Premature; Xanthine

Indexed keywords

CAFFEINE; STEROID; CENTRAL STIMULANT AGENT;

ARTICLE; ARTIFICIAL VENTILATION; BIRTH WEIGHT; BRAIN HEMORRHAGE; CONTROLLED STUDY; EXTUBATION; FEMALE; GESTATIONAL AGE; HOME OXYGEN THERAPY; HUMAN; LENGTH OF STAY; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN DEATH; PATENT DUCTUS ARTERIOSUS; PREMATURITY; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME TO TREATMENT; BRONCHOPULMONARY DYSPLASIA; EPIDEMIOLOGY; MORTALITY; PREGNANCY; TREATMENT OUTCOME; UNITED STATES;

BRONCHOPULMONARY DYSPLASIA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PREGNANCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84907814304     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2014.885941     Document Type: Article

References (31)

1. Bhandari A, Bhandari V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics 2009;123: 1562-73
2. Ambalavanan N, Carlo WA, D'Angio CT, et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics 2009;123: 1132-41
3. Viscardi RM, Muhumuza CK, Rodriguez A, et al. Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res 2004;55: 1009-17
4. Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev 2003;14: 523-35
5. Aghai ZH, Faqiri S, Saslow JG, et al. Angiopoietin 2 concentrations in infants developing bronchopulmonary dysplasia: attenuation by dexamethasone. J Perinatol 2008;28: 149-55
6. Aghai ZH, Saslow JG, Meniru C, et al. High-mobility group box-1 protein in tracheal aspirates from premature infants: relationship with bronchopulmonary dysplasia and steroid therapy. J Perinatol 2010;30: 610-15
7. Jonsson B, Tullus K, Brauner A, et al. Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 1997;77: F198-201
8. Choi CW, Kim BI, Kim HS, et al. Increase of interleukin-6 in tracheal aspirate at birth: a predictor of subsequent bronchopulmonary dysplasia in preterm infants. Acta Paediatr 2006;95: 38-43
9. Munshi UK, Niu JO, Siddiq MM, Parton LA. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol 1997;24: 331-6
10. Chavez-Valdez R, Wills-Karp M, Ahlawat R, et al. Caffeine modulates TNF-Alpha production by cord blood monocytes: the role of adenosine receptors. Pediatr Res 2009;65: 203-8
11. Weichelt U, Cay R, Schmitz T, et al. Prevention of hyperoxiamediated pulmonary inflammation in neonatal rats by caffeine. Eur Respir J 2013;41: 966-73
12. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354: 2112-21
13. Davis PG, Schmidt B, Roberts RS, et al. Caffeine for apnea of prematurity trial: benefits may vary in subgroups. J Pediatr 2010; 156: 382-7
14. Patel RM, Leong T, Carlton DP, Vyas-Read S. Early caffeine therapy and clinical outcomes in extremely preterm infants. J Perinatol 2013;33: 134-40
15. Erenberg A, Leff RD, Haack DG, et al. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebocontrolled study. Pharmacotherapy 2000;20: 644-52
16. Kim BI, Lee HE, Choi CW, et al. Increase in cord blood soluble E-selectin and tracheal aspirate neutrophils at birth and the development of new bronchopulmonary dysplasia. J Perinat Med 2004;32: 282-7
17. Li J, Li G, Hu JL, et al. Chronic or high dose acute caffeine treatment protects mice against oleic acid-induced acute lung injury via an adenosine A2A receptor-independent mechanism. Eur J Pharmacol 2011;654: 295-303
18. Bohrer B, Silveira RC, Neto EC, Procianoy RS. Mechanical ventilation of newborns infant changes in plasma pro-And antiinflammatory cytokines. J Pediatr 2010;156: 16-19
19. Aranda JV, Turmen T, Davis J, et al. Effect of caffeine on control of breathing in infantile apnea. J Pediatr 1983;103: 975-8
20. Davis JM, Bhutani VK, Stefano JL, et al. Changes in pulmonary mechanics following caffeine administration in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1989; 6: 49-52
21. Supinski GS, Deal Jr. EC, Kelsen SG. The effects of caffeine and theophylline on diaphragm contractility. Am Rev Respir Dis 1984; 130: 429-33
22. Yoder B, Thomson M, Coalson J. Lung function in immature baboons with respiratory distress syndrome receiving early caffeine therapy: a pilot study. Acta Paediatr 2005;94: 92-8
23. Schmidt B, Roberts R, Millar D, Kirpalani H. Evidencebased neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology 2008;93: 284-7
24. Thomas W, Speer CP. Nonventilatory strategies for prevention and treatment of bronchopulmonary dysplasia-what is the evidence? Neonatology 2008;94: 150-9
25. Volpe J, ed. Neurology of the newborn. Philadelphia (PA): WB Saunders; 2001
26. Bauer J, Maier K, Linderkamp O, Hentschel R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics 2001;107: 660-3
27. Hoecker C, Nelle M, Poeschl J, et al. Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants. Pediatrics 2002; 109: 784-7
28. Lane AJ, Coombs RC, Evans DH, Levin RJ. Effect of caffeine on neonatal splanchnic blood flow. Arch Dis Child Fetal Neonatal Ed 1999;80: F128-9
29. Soraisham AS, Elliott D, Amin H. Effect of single loading dose of intravenous caffeine infusion on superior mesenteric artery blood flow velocities in preterm infants. J Paediatr Child Health 2008;44: 119-21
30. Robinson MJ, Clayden GS, Smith MF. Xanthines and necrotising enterocolitis. Arch Dis Child 1980;55: 494-5
31. Administration FaD. New drug application: Cafcit (NDA) 020793.Washington, DC, 2000